ANALYSIS: The creative opportunism of an already transformative streaming service is being closely scrutinised.
ANALYSIS: The craze for Ozempic may have contributed to ASX-listed CSL’s success having hiccups this year, but some analysts see a buying opportunity
ANALYSIS: Debate on underlying causes of economic cycles key when ascribing reasons for recovery.
ANALYIS: John le Carré used his spycraft charm to seduce women for his characters.
ANALYSIS: A reminder that trustees can be personally liable for breaching their duty to invest prudently, diversely.
ANALYSIS: Whether a look to the past can help form expectations about what might occur in the future.
ANALYSIS: Shareholders have legitimate concerns about the independence of listed publican’s sale.
ANALYSIS: If giant offshore windfarms require price support mechanisms to be viable, the incoming Government will not be keen.
ANALYSIS: Introducing 10 bills to Parliament – which still have to be drafted – will take time.
ANALYSIS: NBR Listers’ pharma company cleared a major FDA hurdle last week but winning the US is far from assured.